Cargando…

Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine

BACKGROUND: Protection against herpes zoster (HZ) induced by the live attenuated zoster vaccine Zostavax (ZVL) wanes within 3–7 years. Revaccination may renew protection. We assessed whether (re)vaccination with the adjuvanted HZ subunit vaccine candidate (HZ/su) induced comparable immune responses...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grupping, Katrijn, Campora, Laura, Douha, Martine, Heineman, Thomas C, Klein, Nicola P, Lal, Himal, Peterson, James, Vastiau, Ilse, Oostvogels, Lidia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Major Articles and Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5853346/ https://www.ncbi.nlm.nih.gov/pubmed/29029122 http://dx.doi.org/10.1093/infdis/jix482

Ejemplares similares

Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine: A Phase III, Group-Matched, Clinical Trial
por: Grupping, Katrijn, et al.
Publicado: (2017)

Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older
por: Schwarz, Tino F, et al.
Publicado: (2017)

Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial
por: Godeaux, Olivier, et al.
Publicado: (2017)

1956. Persistence of Immune Response and Safety of an Adjuvanted Recombinant Zoster Vaccine in Older Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine: End-of-Study Results of a Phase III, Group-Matched, Clinical Trial
por: Mrkvan, Tomas, et al.
Publicado: (2018)

Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination
por: Bruxvoort, Katia J, et al.
Publicado: (2022)

Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly
por: Vink, Peter, et al.
Publicado: (2016)

Herpes Zoster and Recurrent Herpes Zoster
por: Shiraki, Kimiyasu, et al.
Publicado: (2017)

The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older
por: Cunningham, Anthony L, et al.
Publicado: (2018)

Herpes Zoster Vaccination
por: Kim, Kyung Hoon
Publicado: (2013)

Herpes Zoster Vaccines
por: Harbecke, Ruth, et al.
Publicado: (2021)

Trends in Hospitalizations With Primary Varicella and Herpes Zoster During the Prevaricella and Initial Postvaricella and Herpes Zoster Vaccine Eras, Connecticut, 1994–2012
por: Humes, Elizabeth A., et al.
Publicado: (2015)

Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster
por: Ulaszewska, Marta, et al.
Publicado: (2023)

Herpes zoster vaccine in Korea
por: Choi, Won Suk
Publicado: (2013)

Vaccine against herpes zoster
por: Pasternak, Jacyr
Publicado: (2013)

Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ/su): A phase-I, open-label study in Japanese adults
por: Lal, Himal, et al.
Publicado: (2013)

Herpes zoster ophthalmicus or Herpes zoster maxillaris?
por: Chandravanshi, Shivcharan Lal, et al.
Publicado: (2009)

Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines
por: Marra, Yasmin, et al.
Publicado: (2022)

Status of Herpes Zoster and Herpes Zoster Vaccines in 2023: A position paper
por: García, José María Molero, et al.
Publicado: (2023)

Humoral and Cellular Immunogenicity of Zoster Vaccine within One Year after Herpes Zoster
por: Lee, Eunyoung, et al.
Publicado: (2017)

Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study
por: Berkowitz, Elchonon M., et al.
Publicado: (2015)

Cost-Effectiveness of Herpes Zoster Vaccination
por: Sriwijitalai, Won, et al.
Publicado: (2019)

Herpes zoster after COVID vaccination
por: van Dam, C.S., et al.
Publicado: (2021)

Herpes Zoster and Immunogenicity and Safety of Zoster Vaccines in Transplant Patients: A Narrative Review of the Literature
por: Wang, Lei, et al.
Publicado: (2018)

Healthy ageing: Herpes zoster infection and the role of zoster vaccination
por: Curran, Desmond, et al.
Publicado: (2023)

Herpes zoster following COVID-19 vaccination in an immunocompetent and vaccinated for herpes zoster adult: A two-vaccine related event?
por: Vallianou, Natalia G., et al.
Publicado: (2022)

Assessment of the potential public health impact of Herpes Zoster vaccination in Germany
por: Curran, Desmond, et al.
Publicado: (2017)

Risk Factors for Herpes Zoster Among Adults
por: Marin, Mona, et al.
Publicado: (2016)

Effectiveness of Live Zoster Vaccine in Preventing Herpes Zoster Ophthalmicus (HZO)
por: Aukes, Laurie, et al.
Publicado: (2017)

Herpes Zoster: the rationale for the introduction of vaccination in Italy
por: PAGANINO, C., et al.
Publicado: (2015)

Update on Recommendations for Use of Herpes Zoster Vaccine
por: Hales, Craig M., et al.
Publicado: (2014)

Vaccines for preventing herpes zoster in older adults
por: Gagliardi, Ana M. Z., et al.
Publicado: (2014)

Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in Adults with Hematologic Malignancies: A Phase III, Randomized Clinical Trial
por: Oostvogels, Lidia
Publicado: (2017)

A Cost-effectiveness Analysis of an Adjuvanted Subunit Vaccine for the Prevention of Herpes Zoster and Post-herpetic Neuralgia
por: Carpenter, Christopher F, et al.
Publicado: (2019)

Healthy ageing: Herpes zoster infection and the role of the adjuvanted recombinant zoster vaccine
por: Curran, D, et al.
Publicado: (2022)

Mitochondrial Haplogroups as a Risk Factor for Herpes Zoster
por: Levinson, Rebecca T., et al.
Publicado: (2016)

Incidence of Herpes Zoster and Persistent Post-Zoster Pain in Adults With or Without Diabetes in the United States
por: Suaya, Jose A., et al.
Publicado: (2014)

Varicella and herpes zoster vaccine development: lessons learned
por: Warren-Gash, Charlotte, et al.
Publicado: (2017)

Reactivation of Herpes Zoster Keratitis Following Shingrix Vaccine
por: Lu, Tracy J., et al.
Publicado: (2022)

Covid-19 vaccination and possible link to Herpes zoster
por: Lazzaro, D.R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k71057g34j3ulfion75quktpev